This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• Datamonitor Healthcare estimates that in 2017, there were 559,800 incident cases of thyroid cancer worldwide, and expects that number to increase to 612,600 incident cases by 2026.
• In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.2 million cases by 2026.
• The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
• There are only two industry-sponsored drugs in active clinical development for thyroid cancer, with one each in Phase I and Phase II.
• Therapies in active clinical development for thyroid cancer target carcinoembryonic antigen, the immune system, autologous chimeric antigen receptor T-cells (CAR-T), intercellular adhesion molecule-1, stem cells/other cell therapies, and T lymphocytes. One of the two therapies is being tested in a subcutaneous formulation, while the route of administration of the other is currently unknown.
• The only high-impact upcoming event in the thyroid cancer space is an expected PDUFA date for Cabometyx / Cometriq. The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
• The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 33 trials.
• Novartis leads industry sponsors with the highest overall number of clinical trials for thyroid cancer, followed by Pfizer.